Table 2.

The cost and outcome results of the cost-effectiveness analysis.

Group	C ($)	Incr C	E (QALY)	Incr E	ICER($/QALY)
R-CHOP	31015.38		5.59
Pola-R-CHP	62819.42	31804.04	5.88	0.29	110593.81

Abbreviations: Pola-R-CHP, polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; C, cost; E, effectiveness; Incr C, Incremental Cost; Incr E, Incremental Effectiveness; ICER, Incremental Cost-Effectiveness Ratio.